Point-of-Care Testing

Fiallos, Mariano; Hanhan, Usama A.; Orlowski, James P.

doi:10.1016/s0031-3955(05)70329-1

Cited by 10 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sight OLO offers a full CBC utilizing only 27 μl of blood sample, providing substantial blood conservation for oncology, neonatal and pediatric patients 19 . While OLO is currently indicated for use in patients 3 months and older, further studies are currently being conducted to increase the population range.…”

Section: Discussionmentioning

confidence: 99%

An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology

Bachar¹,

Benbassat²,

Brailovsky³

et al. 2021

American J Hematol

View full text Add to dashboard Cite

Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision.Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-fingerprick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.

show abstract

Section: Discussionmentioning

confidence: 99%

An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology

Bachar¹,

Benbassat²,

Brailovsky³

et al. 2021

American J Hematol

View full text Add to dashboard Cite

show abstract

“…This risk can be decreased or eliminated by timely diagnostic tests. One approach to improving timeliness of tests is point-of-care testing (12). Interestingly, the highest demand for point-of-care testing comes from ICU clinicians and the most frequently cited reason is speed of service (13).…”

Section: Discussionmentioning

confidence: 99%

Computerized physician order entry of diagnostic tests in an intensive care unit is associated with improved timeliness of service

Thompson

Dodek

Norena

et al. 2004

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…Sight OLO offers a full CBC utilizing only 27µL of blood sample, providing substantial blood conservation for oncology, neonatal and pediatric patients (19). While OLO is currently indicated for use in patients 3 months and older, further studies are currently being conducted to increase the population range.…”

Section: Matrix Comparisonmentioning

confidence: 99%

An Artificial Intelligence-Assisted Diagnostic Platform for Rapid Near-Patient Hematology

Bachar¹,

Benbassat²,

Brailovsky³

et al. 2021

Preprint

View full text Add to dashboard Cite

Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.

show abstract

Point-of-Care Testing

Cited by 10 publications

References 29 publications

An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology

An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology

Computerized physician order entry of diagnostic tests in an intensive care unit is associated with improved timeliness of service

An Artificial Intelligence-Assisted Diagnostic Platform for Rapid Near-Patient Hematology

Contact Info

Product

Resources

About